Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram in Major Depression with Diabetes
NCT00650897Phase 4
Key facts
- Status
- Unknown
- Start
- Apr 2008
- Primary completion
- Jun 2009
- Countries
- 1
- Sponsor
- Sheba Medical Center
- Modality
- Small Molecules
- Drugs
- escitalopram
- Conditions
- major depressive disorder (MDD)
01
Overview
Phase 4, open-label, single-arm trial of escitalopram in major depressive disorder (MDD), sponsored by Sheba Medical Center. Primary endpoint: Depressive symptoms at 14 weeks. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Experimental Arm
Patients with Diabetes Mellitus and Major Depression receiving Escitalopram
03
Who it enrols
Adult patients with Type 1 or Type 2 diabetes and major depression (HAMD > 17). Excludes patients with bipolar disorder, psychosis, substance abuse, or significant suicide risk.
04
Endpoints
Primary
Depressive symptoms
Secondary
Diabetes self-care
Beyond the preview
Go deeper on NCT00650897.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00650897.